RecruitingNCT00943514
Respiratory
Primary Ciliary Dyskinesia
Also known as PCD, immotile cilia syndrome, Kartagener syndrome
Primary ciliary dyskinesia is a genetically heterogeneous disorder caused by defects in the structure or function of motile cilia, impairing mucociliary clearance throughout the airways, sinuses, and reproductive tract. Approximately 50% of
ORPHA:244 ↗Gene DNAI1Gene DNAH5Gene DNAH11 (multiple)Prevalence Approximately 1 in 10,000–20,000 live birthsOnset Neonatal / Early childhood
17
studies recruiting now
as of 7 Sept 2026
81
studies registered in total
as of 7 Sept 2026
2
countries with a recruiting site
as of 7 Sept 2026
5 May 2026
most recent study posted
among recruiting studies
Recruiting trials
RecruitingNot applicableNCT07566611
Primary Ciliary Dyskinesia in Adult Bronchiectasis
RecruitingNot applicableNCT03704207
Utility of PCD Diagnostics to Improve Clinical Care
RecruitingNCT00807482
Pathogenesis of Primary Ciliary Dyskinesia (PCD) Lung Disease
RecruitingNCT04798950
Bronchi Dilation in Polynesian Patients: Monocentric Retrospective Study
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 17 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Primary Ciliary Dyskinesia study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
Registry: BESTCILIA PCD Registry · Join ↗. Registries connect patients to researchers and often hear about trials first.
About Primary Ciliary Dyskinesia
Primary ciliary dyskinesia is a genetically heterogeneous disorder caused by defects in the structure or function of motile cilia, impairing mucociliary clearance throughout the airways, sinuses, and reproductive tract. Approximately 50% of patients have situs inversus (Kartagener syndrome) due to randomised organ lateralisation during embryogenesis. The disease leads to chronic sino-pulmonary infections and progressive bronchiectasis if not managed aggressively.
Common clinical features
Neonatal respiratory distressChronic productive cough from infancyRecurrent sinusitis and otitis mediaBronchiectasisSitus inversus or heterotaxy (in ~50%)Male infertility due to immotile spermReduced nasal nitric oxide
From Orphanet’s phenotype annotations (CC BY 4.0). Not a complete list.
Treatments being studied
5 in clinical development, from Open Targets (CC BY 4.0). Not medical advice.
Phase 2Ivacaftor (Ivacaftor component of orkambi)
Phase 2Idrevloride
Phase 2Sodium Chloride (Aqsia (balanced salt soln))
Phase 2Melatonin (Circadin)
Phase 1 (early)Albuterol (Aerolin)
Before you apply
Things trial teams commonly ask about for Primary Ciliary Dyskinesia. Not eligibility rules; those are set by each study.
- Genetic confirmation or nasal nitric oxide measurement below accepted thresholds is commonly required for enrolment; gather diagnostic test results before applying.
- Many trials stratify by specific gene mutation (e.g., DNAI1 vs. DNAH5); confirm your genotype with a certified genetics laboratory.
- Some studies require a stable pulmonary status for 4–6 weeks prior to enrolment, so avoid applying during an active exacerbation.
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).